Alphatec Holdings, Inc. Announces Participation at the 19th Annual Rodman & Renshaw Global Investment Conference
August 30 2017 - 4:10PM
Alphatec Holdings, Inc. (“Alphatec” or the “Company”)
(Nasdaq:ATEC), a provider of innovative spine surgery solutions
with a mission to improve patient lives through the relentless
pursuit of superior outcomes, today announced it will present at
the 19th Annual Rodman & Renshaw Global Investment Conference
on September 11, 2017, at 12:30 P.M. EDT. The conference is
sponsored by H.C. Wainwright & Co., LLC, and is being
held on September 10-12, 2017 at Lotte New York Palace Hotel
in New York City.
Terry Rich, CEO of Alphatec, will provide an
overview of the Company's business during the live
presentation. Management will also be available to
participate in one-on-one meetings with investors who are
registered to attend the conference.
If you are an institutional investor, and would
like to attend the Company’s presentation, please click on the
following link (www.rodmanevents.com) to register for the Rodman
& Renshaw conference. Once your registration is
confirmed, you will be prompted to log into the conference website
to request a one-on-one meeting with the Company.
Event: |
|
|
19th Annual Rodman
& Renshaw Global Investment Conference |
Date: |
|
|
September 11, 2017 |
Time: |
|
|
12:30 p.m. (Eastern
Time) |
Location: |
|
|
Adams Room; Lotte New
York Palace Hotel in New York City |
A copy of the presentation will be available online from the
investor relations page of the Company's corporate website at
www.alphatecspine.com. The conference will be webcast live.
To access the webcast, please visit www.rodmanevents.com. The
webcast replay will remain available for 90 days following the live
presentation.
About Alphatec Holdings,
Inc.
Alphatec Holdings, Inc., through its wholly
owned subsidiary Alphatec Spine, Inc., is a medical device company
that designs, develops, and markets spinal fusion technology
products and solutions for the treatment of spinal disorders
associated with disease and degeneration, congenital deformities,
and trauma. The Company's mission is to improve lives by providing
innovative spine surgery solutions through the relentless pursuit
of superior outcomes. The Company markets its products in the U.S.
via independent sales agents and a direct sales force.
Additional information can be found at
www.alphatecspine.com.
Forward-Looking Statements
Statements made in this press release and made during the
investor events referenced herein may contain "forward-looking
statements" within the meaning of the Private Securities Litigation
Reform Act of 1995 that involve risks and uncertainty. Such
statements are based on management's current expectations and are
subject to a number of risks and uncertainties that could cause
actual results to differ materially from those described in the
forward-looking statements. The Company cautions investors that
there can be no assurance that actual results or business
conditions will not differ materially from those projected or
suggested in such forward-looking statements as a result of various
factors. Forward-looking statements include the references to
the Company's strategy in significantly repositioning the Alphatec
brand and turning the Company into a growth organization. The
important factors that could cause actual operating results to
differ significantly from those expressed or implied by such
forward-looking statements include, but are not limited to:
the uncertainty of success in developing new products or
products currently in the Company's pipeline; the uncertainties in
the Company's ability to execute upon its strategic operating plan;
the uncertainties regarding the ability to successfully license or
acquire new products, and the commercial success of such products;
failure to achieve acceptance of the Company's products by the
surgeon community, including Battalion and Arsenal Deformity;
failure to obtain FDA or other regulatory clearance or approval for
new products, or unexpected or prolonged delays in the process;
continuation of favorable third party reimbursement for procedures
performed using the Company's products; unanticipated expenses or
liabilities or other adverse events affecting cash flow or the
Company's ability to successfully control its costs or achieve
profitability; uncertainty of additional funding; the Company's
ability to compete with other competing products and with emerging
new technologies; product liability exposure; an unsuccessful
outcome in any litigation in which the Company is a defendant;
patent infringement claims; claims related to the Company's
intellectual property and the Company's ability to meet its
financial obligations under its credit agreements and the Orthotec
settlement agreement. The words "believe," "will," "should,"
"expect," "intend," "estimate" and "anticipate," variations of such
words and similar expressions identify forward-looking statements,
but their absence does not mean that a statement is not a
forward-looking statement. A further list and description of
these and other factors, risks and uncertainties can be found in
the Company's most recent annual report, and any subsequent
quarterly and periodic reports, filed with the Securities and
Exchange Commission. Alphatec disclaims any intention or obligation
to update or revise any forward-looking statements, whether as a
result of new information, future events, or otherwise, unless
required by law.
Investor/Media Contact:
Zack Kubow
The Ruth Group
(646) 536-7000
alphatec@theruthgroup.com
Company Contact:
Jeff Black
Executive Vice President and Chief Financial Officer
Alphatec Holdings, Inc.
(760) 431-9286
investorrelations@alphatecspine.com
Alphatec (NASDAQ:ATEC)
Historical Stock Chart
From Mar 2024 to Apr 2024
Alphatec (NASDAQ:ATEC)
Historical Stock Chart
From Apr 2023 to Apr 2024